The Impact of Atorvastatin on Cardiac Performance for Dilated Cardiomyopathy: A Meta-analysis of Randomized

Related Experiment Video

Updated: Dec 18, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Lin Fu1, Xiaoyang Shang1, Xiaoshan Zhang1

  • 1Department of Ultrasonic, The Affiliated Hospital of Neimogo Medical University, Neimogo, China.

The Heart Surgery Forum
|June 12, 2020
PubMed

Insights

Atorvastatin significantly improves cardiac function and reduces inflammation in patients with dilated cardiomyopathy. This meta-analysis of randomized controlled trials confirms atorvastatin

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Dilated cardiomyopathy (DCM) is a complex cardiac condition with significant morbidity and mortality.
  • The role of statins, specifically atorvastatin, in managing DCM remains a subject of ongoing research and debate.
  • Understanding the impact of atorvastatin on cardiac performance and inflammatory markers is crucial for optimizing DCM treatment strategies.

Purpose of the Study:

  • To systematically review and meta-analyze existing randomized controlled trials (RCTs).
  • To evaluate the influence of atorvastatin on cardiac performance and surrogate markers in patients with dilated cardiomyopathy.
  • To provide evidence-based conclusions regarding the efficacy of atorvastatin for DCM.

Main Methods:

  • A comprehensive literature search was conducted across major databases (PubMed, Embase, Web of Science, EBSCO, Cochrane Library) through February 2019.
  • Randomized controlled trials (RCTs) investigating the effects of atorvastatin on cardiac performance in DCM patients were included.
  • A random-effects model was employed for the meta-analysis to synthesize the data from five RCTs involving 401 patients.

Main Results:

  • Atorvastatin treatment significantly improved left ventricular ejection fraction (SMD = 0.58) and 6-minute walk test distance (SMD = 0.79).
  • The drug led to a significant reduction in N-terminal pro-brain natriuretic peptide (SMD = -0.60) and C-reactive protein (SMD = -0.47), indicating reduced cardiac strain and inflammation.
  • Significant improvements were also observed in left ventricular systolic volume (SMD = 0.41) and low-density lipoprotein levels (SMD = -1.37), with no significant effect on left ventricular end-diastolic volume.

Conclusions:

  • Atorvastatin demonstrates significant benefits in improving cardiac function and reducing key biomarkers in patients with dilated cardiomyopathy.
  • The findings support the use of atorvastatin as an effective therapeutic agent for managing dilated cardiomyopathy.
  • Further research may explore long-term outcomes and specific patient subgroups who benefit most from atorvastatin therapy.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
214
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
319
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
796
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
664